SCOLR Pharma, Inc. today announced that the U. S. FDA has issued a Complete Response letter for its Abbreviated New Drug Application for pseudoephedrine. The application, filed by SCOLR on August 5, 2008, seeks approval to market a 120 mg 12 hour pseudoephedrine tablet based on its patented Controlled Delivery Technology (CDT(R)) platform.
The details can be read here.
No comments:
Post a Comment